semaglutide dementia Associations of with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US - Wang - 2024 Study Shows Some Weight Loss
Description
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market
GLP-1 prescriptions for those aged 18 to 39 increased 588%, from 0.19% in 2019 to 1.33% in 2024
Treatment Scope: According to company materials, the platform offers 45+ treatments across longevity, weight management, energy optimization, cardiovascular health, and cognitive function categories
Mechanisms and potential targets of GLP-1RAs Neuroprotective effects The established anti-inflammatory and neuroprotective effects of GLP-1RAs within the central nervous system suggest their therapeutic potential across a spectrum of neurodegenerative disorders [40, 41]
This is problematic because muscle mass contributes to metabolic rate, functional capacity, and long-term health
[DOI] [PubMed] [Google Scholar] 223.US Congress
